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Abstract
Background: Statin treatment has been associated with a beneficial outcome on respiratory tract infections. In addition,
previous in vitro and in vivo experiments have indicated favorable effects of statins in bacterial infections.
Aim: The aim of the present study was to elucidate possible antibacterial effects of statins against primary pathogens of the
respiratory tract.
Methods: MIC-values for simvastatin, fluvastatin and pravastatin against S. pneumoniae, M. catarrhalis and H. influenzae were
determined by traditional antibacterial assays. A BioScreen instrument was used to monitor effects of statins on bacterial
growth and to assess possible synergistic effects with penicillin. Bacterial growth in whole blood and serum from healthy
volunteers before and after a single dose of simvastatin, fluvastatin and penicillin (positive control) was determined using a
blood culture system (BactAlert).
Findings: The MIC-value for simvastatin against S pneumoniae and M catarrhalis was 15 mg/mL (36 mmol/L). Fluvastatin and
Pravastatin showed no antibacterial effect in concentrations up to 100 mg/mL (230 mmol/L). Statins did not affect growth or
viability of H influenzae. Single doses of statins given to healthy volunteers did not affect growth of pneumococci, whereas
penicillin efficiently killed all bacteria.
Conclusions: Simvastatin at high concentrations 15 mg/mL (36 mmol/L) rapidly kills S pneumoniae and M catarrhalis.
However, these concentrations by far exceed the concentrations detected in human blood during simvastatin therapy (1–
15 nmol/L) and single doses of statins given to healthy volunteers did not improve antibacterial effects of whole blood.
Thus, a direct bactericidal effect of statins in vivo is probably not the mechanism behind the observed beneficial effect of
statins against various infections.
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Introduction
Statins (HMG-CoA reductase inhibitors) are today some of the
most prescribed drugs in the world due to their beneficial effects
on cardiovascular disease [1]. During recent years statins have
been ascribed additional beneficial (pleitropic) effects. This
includes anti-inflammatory [2], immunomodulatory [3] and
anticarcinogenic properties [4,5]. In addition, a number of
observational studies support that statin treatment is associated
with a better prognosis in severe bacterial infections [6,7].
According to a meta-analysis of these studies patients on statin
therapy seem to have a better outcome of bacterial infections
(OR 0.53, 95% CI 0.42–0.66). However, the association did not
reach statistical significance after adjustment for apparent
publication bias OR 0.79 (95% CI 0.58–1.07). The proposed
effect of statin seems to be particularly pronounced in respiratory
tract infection. Of 15 observational studies on pneumonia and
statins, 12 showed that statin-use was associated with a favourable
outcome [6].
This proposed beneficial effect of statins might be explained by
potential anti-inflammatory properties [2]. In addition, statins
have been reported to inhibit host cell invasion by Staphylococcus
aureus [8] as well as to enhance bacterial clearance of this pathogen
[9]. A direct antibacterial effect of statins against Staphylococcus
aureus has also been proposed [10,11]. Moreover, statins have been
shown to protect against pneumococcal infection in a mouse
model of sickle cell disease [12]. Recently, statins were shown to
improve killing of Staphylococcus aureus by phagocytic cells [13].
However, all in vitro experiments mentioned above have been
performed using statin concentrations between 0.1–50 mM, which
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24394greatly exceeds the concentrations present in human blood during
statin treatment (1–15 nmol/L) [14].
The aim of the present study was to investigate possible direct
antibacterial effect(s) of statins in vitro and in vivo. Since both
epidemiological end experimental data have shown positive effects
of statins in respiratory tract infections we here focus on the major
respiratory pathogen Streptococcus pneumoniae (the pneumococcus).
Methods
Chemicals
Simvastatin (lactone and hydroxy acid forms) were purchased
from Toronto Research Chemicals. Fluvastatin was obtained
from Tocris Bioscience. Pravastatin, Dimethyl sulphoxide
(DMSO), Methanol and Mevalonic acid were obtained from
Sigma Aldrich.
Bacterial strains and growth conditions
The serotype 4 Streptococcus pneumoniae strain T4 (TIGR4; ATCC
BAA-334) [15] and the non-encapsulated laboratory strain R6
were used. Pneumococci were grown overnight on blood agar
plates at 37uC and colonies were inoculated into C+Y medium.
Haemophilus influenzae and Moraxella catarrhalis were clinical isolates
whose identity were confirmed by 16S RNA sequencing by
Clinical Microbiology, Karolinska University Hospital, Solna [16].
H. influenzae and M. catarrhalis were grown overnight on hematin
Figure 1. A. Simvastatin kills S. pneumoniae strain T4 in a concentration dependent manner. Approximately 1610
5 CFU of streptococci was
incubated for 3–4 hours with various concentrations of simvastatin dissolved in DMSO diluted to a final concentration of 2.5%. The MIC-value was
determined to 15.6 mg/ml (36 mmol/L). DMSO (2.5%) alone did not exert any bactericidal effects. The concentrations are calculated and presented in
micrograms/ml. Experiments were performed 5 times in triplicates with identical MIC-values. A representative experiment is shown +/- SEM. B. Rapid
killing of S. pneumoniae by simvastatin after 60 minutes. The CFU value for T4 + SIM after 60 minutes is significantly lower compared to baseline
(p=0.03). Experiments were performed 3 times in triplicates with identical kinetics. A representative experiment is shown +/- SEM. C. Effect of lactone
(SIM) and hydroxy acid (SIM-OH) forms of simvastatin against S. pneumoniae T4. Methanol (MET, 2.5%) and DMSO (2.5%) were used solvents for the
chemicals, which were investigated at equimolar concentrations for bacterial killing. The CFU value for SIM MET and SIM DMSO at 50 mMi s
significantly lower than baseline (p=0.02) and than the CFU values for SIM-OH MET and SIM-OH DMSO at 50 mM (p=0.03). Experiments were
performed 3 times in triplicates with similar results. A representative experiment is shown +/- SEM. D. Effects of the hydrophilic pravastatin against S.
pneumoniae. Pravastatin was compared with simvastatin at equimolar concentrations. The concentrations are calculated and presented in
micromolar. The CFU value for SIM at 31.25 mM was significantly lower than baseline (p=0.02). Experiments were performed 3 times in triplicates with
similar results. A representative experiment is shown +/- SEM. Panels A, C and D: Bacteria (1–2610
5 CFU) and statins were co-incubated for 3–4 hours,
the mixtures were serially diluted and plated. Surviving colonies (CFU) were counted after over night incubation. Mann Whitney U-test was used for
statistical analyses.
doi:10.1371/journal.pone.0024394.g001
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heart infusion (BHI-medium) +2% Fildes supplement (Oxoid).
Bacteria were grown in 37uC to mid logarithmic phase and
subsequently used for antibacterial assays and BioScreen-system
experiments.
Bacterial killing assay
Simvastatin was dissolved in 100% DMSO or 100% methanol.
Dilution series (1:2) in 8 steps were prepared in 100% DMSO with
stock solutions (x 40) having concentrations from 10 mM (final
concentration in each tube =250 mg/ml) to 78 mmol/L (final
concentration =1.95 mg/ml). Five mL of the simvastatin/DMSO-
solution was added to the experimental vials resulting in a final
DMSO-concentration of 2.5% in each vial. To this 50 mL
bacterial suspension and 145 mL medium was added to obtain a
final volume of 200 mL. The tubes were gently shaken and
incubated for various times (30 minutes–4 hours) in 37uC. The
Figure 2. Effects of mevalonate (MEV) on bacterial killing by
simvastatin. Different concentrations of mevalonate (0.6 mM–10 mM)
were incubated with S. pneumoniae alone or together with simvastatin
(15.6 mg/ml or 36 mmol/L) or with DMSO (2.5%). Mevalonate could not
rescue the simvastatin mediated killing of pneumococci up to
concentrations of 10 mM. The empty column designates the positive
control (bacteria +buffer), gray columns: experiments with mevalonate
(different concentrations) and the black column stands for 10 mM
mevalonate +2.5% DMSO. The experiment was performed 3 times in
triplicate with similar results, a representative experiment is shown +/-
SEM.
doi:10.1371/journal.pone.0024394.g002
Figure 3. Effects of simvastatin against H. influenzae and M.
catarrhalis. Bacteria (1–2610
5 CFU for M. catarrhalis and 5610
6 CFU for
H. influenzae) and different concentrations of statins were co-incubated
for 3–4 hours, the mixtures were serially diluted and plated. Surviving
colonies (CFU) were counted after over night incubation. The CFU
counts for M catarrhalis at 15.6 mg/ml of simvastatin was significantly
lower than baseline (p=0.04). The experiment was performed 3 times in
triplicate with similar results. A representative experiment is shown +/-
SEM. Mann Whitney U-test was used for statistical analyses.
doi:10.1371/journal.pone.0024394.g003
Figure 4. Effect of capsule on simvastatin mediated killing of S.
pneumoniae. Strains T4 (encapsulated) and R6 (non-encapsulated)
were compared for sensitivity of simvastatin mediated killing. Bacteria
(1–2610
5 CFU) and simvastatin were co-incubated for 3–4 hours, the
mixtures were serially diluted and plated. Surviving colonies (CFU) were
counted after over night incubation and an identical MIC value
(15.6 mg/ml) was obtained for the two strains. The experiment was
performed 3 times in triplicate with similar results, a representative
experiment is shown +/- SEM.
doi:10.1371/journal.pone.0024394.g004
Figure 5. Effects of DMSO and simvastatin on pneumococcal
growth. Bacteria were grown to midlogarithmic phase and diluted to
OD 0.05. The suspension was co-incubated with simvastatin and DMSO
in a BioScreen instrument. Curve 1: positive control (S. pneumoniae
strain T4). Curve 2: T4 + DMSO (2.5%). Curve 3: T4 + simvastatin at a low
concentration below the MIC-value. Curve 4: T4 + simvastatin at MIC-
concentration (15.6 mg/ml or 36 mmol/L). Arrows indicate when
autolysis was initiated. The experiment was performed 5 times in
duplicates with similar results, a representative experiment is shown.
doi:10.1371/journal.pone.0024394.g005
Antibacterial Effects of Statins
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5610
6 CFU/mL. After the indicated times, 10–100 mL from
each tube was diluted in PBS and plated on agar plates. After an
over night incubation, numbers of surviving colony forming units
were counted.
BioScreen Experiments
The instrument was purchased from Oy Growth Curves AB,
Finland and special honey well plates were used for these
experiments (www.bioscreen.fi). In brief, a similar procedure as
described above was used for statin and bacterial dilutions and
preparations. However, the main difference was that for the
antibacterial assays, bacteria were grown to OD600 0.2, whereas
the BioScreen experiments were started with bacteria diluted from
midlogarithmic phase down to OD600 0.05. This was important
in order to synchronize the cultures and to obtain comparable
curves between different experiments and between wells. The
readout was performed using the software provided by the
manufacturer. Data were further processed in Microsoft Excel
and Graph Pad Prism.
In vivo experiments on healthy volunteers
The study was approved by the Regional Ethics Committee at
Karolinska Institutet, Stockholm (Dnr 2010/ 834-31/3) and
written informed consent was obtained from all participants prior
to the study. Five healthy volunteers were recruited and given
single doses of Simvastatin, 80 mg (n=3), Fluvastatin, 40 mg
(n=1) and Penicillin (Ka ˚vepenin), 1 g (n=1). Serum and heparin
blood was taken immediately before the tablets were taken and
2 hours after the dose (time of Cmax for simvastatin) [17]. For
Penicillin, the second blood sample was taken 30 minutes after the
dose, since this is when Cmax occurs [18]. Five millilitres of the
Figure 6. Effects of simvastatin and penicillin (PC-G) on pneumococcal growth. Bacteria was grown to midlogarithmic phase and diluted to
OD 0.05. The suspension was co-incubated with simvastatin, DMSO (2.5%) and penicillin in a BioScreen instrument. Curve 1: positive control (S.
pneumoniae strain T4) + PC-G (0.01 mg/ml). Curve 2: T4 + simvastatin (7.8 mg/ml) in DMSO (2.5%). Curve 3: T4 + PC-G (0.01 mg/ml) + DMSO (2.5%).
Curve 4: T4 + PC-G (0.01 mg/ml) and simvastatin (7.8 mg/ml) in DMSO (2.5%). The experiment was performed 3 times in duplicates with similar results,
a representative experiment is shown.
doi:10.1371/journal.pone.0024394.g006
Table 1. Pneumococcal viability in whole blood as measured in a BactAlert system.
Subject no 1 2 3 4 5
Drug PCV FLU SIM SIM SIM
Conc in plasma
(Cmax, 2h)








374 min 374 min 389 min 374 min 389 min
Time to detection
(after)
.7000 min 374 min 389 min 389 min 389 min
5 healthy individuals were given either 1 gram penicillin-V (PCV), Fluvastatin (Lescol 40 mg) (FLU) or Simvastatin (80 mg) (SIM) a single doses. Blood was taken
immediately before and 30 min (PC-V) and 2 hours (statins) after the intake of the tablets. Concentrations of simvastatin and fluvastatin in serum were measured by LC-
MS/MS. The blood was transferred to blood culture flasks, to which pneumococci (6610
6 CFU) were added. The flasks were gently mixed and thereafter applied to the
BactAlert system. The times indicate ‘‘time to detection of bacterial growth’’ in the system. The flasks are routinely incubated for 5 days (7000 minutes) when they are
taken out and discarded.
doi:10.1371/journal.pone.0024394.t001
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2610
6 CFU of pneumococci strain T4 was added. The flasks
were mixed gently and then applied to the BactAlert-system. The
read-out in this system is based on a chemical detection system,
which set off an alarm when bacterial growth reaches a pre-set
level. Whole blood was also used for antibacterial assays where
800 ml of whole blood was mixed with 200 mL of bacterial
suspension (6610
6 CFU). The tubes were gently mixed during
incubation in 37uC and aliquots of 100 ml were drawn after 1, 2, 3
and 4 hours. The aliquots were plated, incubated and counted as
described above.
Measurements of plasma concentrations of fluvastatin
and simvastatin
Concentrations of simvastatin (SIM), simvastatin-acid (SIM-OH)
and fluvastatin in serum from the healthy volunteers in the in vivo
study was measured by a standard liquid chromatography tandem
mass spectrometry (LC-MS/MS) method developed for SIM, SIM-
OH and fluvastatin as well as for atorvastatin, atorvastatin lactone
and rosuvastatin. Sample preparation was based on pH-controlled
solid phase extraction followed by evaporation under nitrogen and
subsequent reconstitution. Subsequent analysis was performed on a
RP-column with a triple quadrupole mass spectrometer as detector.
Quantification was calculated on analyte/internal standard peak
area ratios with internal standards simvastatin-d6, simvastatin-acid-
d6 and atorvastatin-d5 for SIM, SIM-OH and fluvastatin,
respectively. Quantitation range for all compounds was 0,05–
125 ng/mLwithlimitofdetectionat0,02 ng/mL. This isa recently
established method for clinical use in the Clinical Pharmacology
Laboratory at Karolinska University Hospital, Stockholm, Sweden.
The method is to be described in details elsewhere (Skilving I, et al,
manuscript in preparation).
Statistical analyses
Data was analysed in GraphPad software, version 5.03 for
Windows. The non-parametric Mann Whitney U-test or Wilcoxon
signed rank test were used as indicated in figure legends. A
significance level of p,0.05 was considered as significant.
Results
Simvastatin has bactericidal properties against S.
pneumoniae
The antibacterial activity of Simvastatin was investigated using
the encapsulated pneumococcal strain TIGR4. 100% killing of
viable bacteria was obtained with simvastatin at the concentra-
tion 15.6 mg/mL (36 mmol/L) (Fig 1A). The killing of bacteria
occurred rapidly and a 4-log reduction occurred in 60 minutes
(Fig 1B). Simvastatin is a hydrophobic statin and was dissolved in
2.5% DMSO according to the recommendation of the manu-
facturer. Since DMSO may have antibacterial activities per se,a
DMSO-control (2.5%) was included in these experiments. No
effect on bacterial killing by DMSO alone was observed during
the 180 minutes of incubation during the killing experiments
(Fig 1A). To rule out that an intrinsic or synergistic role of
DMSO could contribute to our results, simvastatin was dissolved
in an alternative solvent (methanol), which produced the same
results as the DMSO-dissolved simvastatin (Fig 1C). For these
experiments we used the simvastatin-lactone, which is an inactive
precursor molecule. To study the potential physiological role of
simvastatin as an antibacterial agent, we also obtained the active
metabolite simvastatin hydroxy acid (SIM-OH) and repeated the
experiments. Interestingly, this metabolite was inactive against
pneumococci at equimolar concentrations as the simvastatin
lactone (Fig 1C). Two other common statins were also
investigated for killing of pneumococci. The hydrophilic prava-
statin was dissolved both in water and in DMSO but failed to
exhibit any bactericidal activity at concentrations up to
125 mmol/L (Fig 1D). Fluvastatin was also tested and did not
exhibit any significant effects at concentrations up to 300 mmol/L
(data not shown).
Simvastatin kills pneumococci independently of HMG-
CoA Reductase
Pneumococci express the target enzyme for statins (HMG-
CoA reductase) and a deletion of the gene encoding this enzyme
has been shown to inhibit bacterial growth [19,20]. Thus, we
used mevalonic acid to rescue blockage of this rate limiting step
in cholesterol synthesis. Notably, the presence of 10 mM of
mevalonic acid did not rescue simvastatin-mediated killing of
pneumococci, which suggest that the killing mechanism does not
involve inhibition of bacterial HMG-CoA reductase (Fig 2).
Simvastatin also kills M. catarrhalis but is inactive against
H. influenzae
The effect of simvastatin was further investigated against two
other bacteria responsible for respiratory tract infections, M.
catarrhalis and H. influenzae. A similar effect could be observed for
simvastatin against M catarrhalis with a MIC-value of 15,6 mg/ml.
In contrast, the growth of H. influenzae was not affected by
simvastatin at concentrations up to 250 mg/ml (600 mmol/L),
suggesting a certain specificity with regards to simvastatin-
mediated bacterial killing (Fig 3).
The role of the pneumococcal capsule in statin-mediated
killing of pneumococci
Since pneumococci constitute a primary pathogen of significant
clinical importance and since they were shown to be sensitive to
simvastatin, we used this bacterial pathogen for the subsequent
Figure 7. Effects of a single dose simvastatin per os on
pneumococcal viability in whole blood. 80 mg simvastatin was
given to a healthy volunteer. Whole blood was taken immediately
before and 2 hours after intake of the tablet. Bacteria (1610
4 CFU) were
mixed with the blood and incubated at 37uC. Aliquots were collected at
various times and plated. After an over night incubation surviving
colonies were counted. There was no statistical significance in CFU
counts in blood drawn before or after intake of simvastatin at any
timepoint (Wilcoxon signed rank test was used for statistical
calculation). The experiment was performed in 3 subjects with similar
results. The data from one subject is shown +/- SEM.
doi:10.1371/journal.pone.0024394.g007
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non-encapsulated pneumococcal strain R6 was used. A similar
pattern of killing was observed for strains R6 and T4, suggesting
that the capsule is not a major determinant for bactericidal effects
of simvastatin (Fig 4).
Growth curves and induction of autolysis
To study the effects of simvastatin on pneumococci in more
detail, bacterial growth curves were generated using a BioScreen-
system. Bacteria were exposed to simvastatin of different
concentrations for 16 hours. A potent growth-inhibiting effect of
simvastatin at a concentration of 15,6 mg/ml was observed (Fig 5,
curve 4). Unexpectedly, we detected an effect on autolysis by 2.5%
DMSO after 5 hours, compared to the natural autolysis in the
untreated TIGR4 control that occurred after 9 hours (Fig 5,
curves 1 and 2). An autolysis-inducing effect was also observed for
simvastatin at the non-bactericidal concentration of 7.8 mg/ml
(Fig 5, curve 3). Importantly, the growth curve for simvastatin was
different than the curve for DMSO alone, indicating that
simvastatin had a specific effect on pneumococci with regards to
autolysis (Fig 5, curves 2 and 3).
Simvastatin and penicillin has an additive effect on
autolysis
The potential synergistic effect between penicillin and simvas-
tatin was investigated using the BioScreen-system. A sub-MIC
concentration of penicillin-G was used (0.01 mg/ml), which alone
did not affect bacterial growth or induction of autolysis (Fig 6,
curve 1). Simvastatin at a non-lethal concentration (7.8 mg/ml)
induced autolysis, similarly to previous experiments (fig 5, curve 2).
Interestingly, the combination of simvastatin and PC-G was
significantly more efficient at inducing autolysis than any of the
compounds alone (Fig 6, curve 4). However, PC-G also exerted
additive effects together with DMSO on autolysis, although this
effect was less pronounced than PC-G used together with
simvastatin (Fig 6, curve 3).
Simvastatin or Fluvastatin do not affect pneumococcal
growth in whole blood ex vivo
The in vitro experiments presented above suggested that
simvastatin could kill pneumococci at a concentration in the
mmol/L-range (MIC=36 mmol/L). To study a potential in vivo
role of statins as antibacterial agents we recruited 5 healthy
volunteers and gave them maximum dose of Simvastatin (80 mg)
or Fluvastatin (40 mg) as single doses. Whole blood was sampled
2 hours later when the serum concentrations were predicted to be
on a maximal level (Cmax) and inoculated into blood culture flasks
together with pneumococci. Plasma concentrations of fluvastatin
was 110.8 nM and for simvastatin 8 nM (acid form, average of 3
individuals) and 19.4 nM (lactone form, average of 3 individuals),
respectively (table 1). Whole blood bacterial killing assays were also
performed. As a control one study subject ingested 1 gram of
Penicillin-V and whole blood was sampled after 30 minutes
(Cmax). Intake of 80 mg simvastatin did not affect bacterial
growth in whole blood during the first 300 minutes of growth
(Fig 7). The blood culture flasks were put into a BactAlert-
detection system and bacterial growth was detected after
approximately 374–389 minutes for all samples, except in blood
derived from study subject 1 after intake of 1 gram PC-V. This
blood culture flask had no bacterial growth and was taken out of
the system after 5 days (7000 minutes) according to the standard
procedure used for clinical work (Table 1).
Discussion
Epidemiological data suggest that statins may have beneficial
effects on mortality during pneumonia [6]. These positive effects
have been ascribed a potential anti-inflammatory response
mediated by statins. In addition, statins have been demonstrated
to exert antibacterial activity per se [10,11]. In this study we
investigated whether statins can have antibacterial activity against
different respiratory pathogens, including S. pneumoniae, H.
influenzae and M. catarrhalis. Using standard antibacterial assays in
liquid broth, we demonstrate MIC-values for simvastatin against S.
pneumoniae and M. catarrhalis of 15 mg/mL (36 mmol/L). Since
pneumococci express the target enzyme for statins, HMG-CoA
reductase, we investigated whether this enzyme was involved in
the observed effect. Notably, mevalonic acid could not rescue the
statin mediated killing of pneumococci, underscoring that
inhibition of HMG-CoA reductase is not involved in the killing
effects. In fact, the true substrate for HMG-CoA reductase, the
hydroxy acid form of simvastatin, did not exert any activity, which
further emphasizes a non-HMG-CoA reductase dependent effect
of simvastatin against pneumococci. We also investigated the
hydrophilic compounds fluvastatin and pravastatin, which did not
affect bacterial growth up to 300 mmol/L. Thus, a likely
mechanism is that the hydrophobic character of simvastatin
perturbs the bacterial membrane in a ‘‘soap-like’’ manner, with
the final result of bacterial death. Interestingly, H. influenzae was
not affected by simvastatin, suggesting specificity with regards to
the underlying mechanism of statin mediated killing of bacteria.
The reason for this statin-resistance of H. influenzae remains to be
elucidated.
We also performed detailed experiments on statin mediated
effects on pneumococci in a BioScreen system, enabling the study
of pneumococcal growth curves for up to 16 hours. Membrane
perturbation in pneumococci by substances such as penicillin [21],
leads to the release of the autolytic enzyme LytA and subsequent
degradation of cell wall peptidoglycan (PGN) and autolysis.
Interestingly, we noted that simvastatin accelerated the induction
of autolysis in pneumococci by 5 hours at sub-MIC doses (Fig 5).
We propose that the hydrophobic nature of simvastatin was
responsible for the release of LytA and PGN-degradation. Despite
the potent effects on autolysis by simvastatin at sub-MIC
concentrations, these effects were not translated into reduced
bacterial growth. However, since simvastatin is a hydrophobic
compound it was dissolved in DMSO, an organic solvent that is
widely used in biological experiments and has been described as
more or less ‘‘inert’’ to bacterial and human cells. Notably, in 1967
Pottz et al. investigated the effects of DMSO on pneumococcal
viability and found that 4% DMSO significantly inhibited
bacterial growth and that no growth occurred at 5% DMSO
[22]. Here we used DMSO at 2.5% and did not observe any
significant effects of DMSO on bacterial viability (Fig 1A and B).
Importantly, even though DMSO did not affect bacterial growth it
did affect membrane integrity since it had a major impact on
autolysis (Fig 5, curve 2). To rule out that all our observed effects
could be attributed to DMSO in the system, we also dissolved
simvastatin in methanol, and the simvastatin-mediated effect on
pneumococcal autolysis could be reproduced, suggesting a true
intrinsic effect of simvastatin (data not shown). Nevertheless, our
data suggest that DMSO should be used with caution in
experiments involving pneumococci, since there are clear effects
on autolysis by this compound.
To study a potential synergistic effect between simvastatin and
antibiotics, we investigated the effect of simvastatin together with a
beta lactam antibiotic (penicillin-G) in the BioScreen assay.
Antibacterial Effects of Statins
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simvastatin on autolysis. This synergy occurred at concentrations
below the MIC levels for the respective drug (7.8 mg/mL or
18 mmol/L).
The mean concentration of statins in human serum is only 1–
15 nmol/L [14]. In addition, the protein binding of statins in
human blood is high, 95–99%, and it is only the free fraction
(0.01–0.5 nmol/L) that is pharmacologically active [14]. Thus, the
MIC-value for simvastatin (15 mg/L or 36 mmol/L) and the
concentration giving synergistic effect on autolysis with PCG
(7.8 mg/L or 18 mmol/L) is approximately 1000-fold higher than
what can be achieved in humans, which strongly argue against any
relevant antibacterial effect of statins in vivo with or without
antibiotics.
However, it could be speculated that statins affect the killing
capacity of immune cells in the blood, as proposed by Chow et al
[13]. Thus, we conducted a small pilot-study where healthy
volunteers were given a single dose of simvastatin or fluvastatin
and blood were collected before and after statin intake. The
positive control was a healthy volunteer taking penicillin. We
compared the growth of bacteria in blood before and after statin
intake. By this approach we studied statins at physiological
concentrations in vivo without the solvents (DMSO or methanol)
that are present in the in vitro experiments. Importantly, bacterial
growth could be detected in all blood flasks at approximately the
same time (374 minutes), whereas the blood flasks from the single
individual taking penicillin did not yield any growth even after 5
days, indicating rapid bacterial killing. Hence, a single dose of
statin does not result in sufficient concentrations for pneumococcal
killing in whole blood. Moreover, our data suggest that a single
dose of statins does not improve monocyte- or neutrophil-
mediated killing of pneumococci in whole blood.
The main limitation of our study is that we only studied a single
dose of statins and we cannot rule out any long term antibacterial
effect of statins in patients taking this drug. Nevertheless, since
many mechanistic studies have been performed using non-
physiological concentrations of statins [14] and that the epidemi-
ological evidence may be flawed by publication bias [6],
randomized controlled trials of statin treatment during infections
are highly warranted.
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